Health Care

GSK PLC expands its global therapeutic reach with approvals for bepirovirsen in Japan, priority reviews in China and Japan, and robust Cabenuva data for adolescents—showcasing safety‑focused, market‑driven progress across infectious, liver, and rare…

RBC’s fresh coverage of Bristol‑Myers Squibb highlights the firm’s robust late‑stage pipeline, strong pricing power, and strategic M&A plans, offering investors a clear view of upside amid upcoming patent cliffs and competitive pressure.

Smith & Ne Phew expands in the U.S. with RMR Ortho, bringing its shape‑memory A’Tomic nitinol fixation system to trauma, foot‑and‑ankle and hand‑and‑wrist markets, promising better healing and lower revision rates.

Elevance Health’s new leadership reshapes care delivery, cutting pharma costs with data‑driven utilization, AI‑enhanced portals, and a $2 M food‑as‑medicine pledge.

Market update: Sartorius AG shares remain flat with modest annual gains; stable performance within TecDAX, no new catalysts yet. Watch earnings for shifts.

Fresenius SE & Co KGaA’s Feb 25, 2026 stock dip shows strong cost‑saving, resilient subsidiaries, and bullish JPMorgan outlook amid a rising DAX, hinting at steady growth in dialysis and pharma for patients and investors alike.

UnitedHealth Group’s $2.21 quarterly dividend reflects strong cash flow, solid ROIC and a competitive yield, yet investors watch its evolving reimbursement model and tech‑driven care expansion for long‑term value.

New partnership with Vivtex could bring oral biologics for obesity and type 2 diabetes, boosting Novo Nordisk’s pipeline while maintaining strong fundamentals and dividend policy.

Fresenius Medical Care Q4 2025 earnings beat expectations, yet stock fell due to 2026 uncertainty. Learn how cost discipline, market risks, and regulatory compliance shape the outlook.

Labcorp Holdings: a steady diagnostics stock with flat gains—discover why its lack of new launches could be a hidden value or a missed AI/biotech opportunity.